Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. (2014)
Attributed to:
Development of enhanced gene specific technology for the isolation of proteins binding at a single locus in vivo.
funded by
BBSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/bjc.2014.35
PubMed Identifier: 24496456
Publication URI: http://europepmc.org/abstract/MED/24496456
Type: Journal Article/Review
Volume: 110
Parent Publication: British journal of cancer
Issue: 5
ISSN: 0007-0920